7576-88-7

Usage

Uses

Used in Organic Chemistry:
2,3-Dimethyl-6-quinoxalinamine is used as a chemical intermediate for the synthesis of various chemical derivatives. Its complex structure and reactivity make it a valuable component in the development of new materials and compounds.
Used in Pharmaceutical Development:
2,3-Dimethyl-6-quinoxalinamine is used as a building block in the creation of new medicinal compounds. Its ability to participate in a wide range of chemical reactions facilitates the design and synthesis of potential drug candidates, contributing to advancements in medicine.
Used in Material Science:
2,3-Dimethyl-6-quinoxalinamine is used as a component in the development of novel materials. Its chemical properties and reactivity enable the production of materials with unique characteristics, such as improved stability or enhanced functionality, which can be applied in various industries.

InChI:InChI=1/C10H11N3/c1-6-7(2)13-10-5-8(11)3-4-9(10)12-6/h3-5H,11H2,1-2H3

Upstream product

• 615-47-4 benzene-1,2,4-triamine dihydrochloride 
• 431-03-8 dimethylglyoxal 
• 2942-03-2 2,3-dimethyl-6-nitroquinoxaline 
• 917-54-4 methyllithium 
• 4188-17-4 2-methyl-6-amino-quinoxaline 
• 99-56-9 4-Nitrophenylene-1,2-diamine 

Downstream Products

• 109671-49-0 N-benzenesulphonyl-2,3-dimethyl-6-quinoxalinamine 
• 109671-46-7 N,N,2,3-tetramethyl-6-quinoxalinamine 
• 60639-47-6 N,2,3-trimethyl-6-quinoxalinamine 
• 170948-50-2 2-[(2,3-dimethylquinoxalin-6-ylamino)methylene]malonic acid diethyl ester 
• 109671-50-3 N-benzenesulphonyl-N,2,3-trimethyl-6-quinoxalinamine 
• 92180-79-5 2-amino-3,7,8-trimethylimidazo[4,5-f]quinoxaline 
• 107095-00-1 N,2,3-trimethyl-5-nitro-6-quinoxalinamine 
• 1369351-96-1 1-(4-bromophenyl)-3-(2,3-dimethylquinoxalin-6-yl)urea 
• 1290058-68-2 N-(2,3-dithienylquinoxalin-6-yl)-N-tosyl-(4-methyl-benzene)sulfonamide 
• 19031-45-9 6-Acetylamino-2,3-dimethyl-chinoxalin 
• 177264-57-2 1-(2,3-dimethylquinoxalin-6-yl)-3-phenylurea 

Relevant academic research and scientific papers

Synthesis, biological evaluation, and in silico studies of new acetylcholinesterase inhibitors based on quinoxaline scaffold

A quinoxaline scaffold exhibits various bioactivities in pharmacotherapeutic interests. In this research, twelve quinoxaline derivatives were synthesized and evaluated as new acetyl-cholinesterase inhibitors. We found all compounds showed potent inhibitory activity against acetyl-cholinesterase (AChE) with IC50 values of 0.077 to 50.080 μM, along with promising predicted drug-likeness and blood–brain barrier (BBB) permeation. In addition, potent butyrylcholinesterase (BChE) inhibitory activity with IC50 values of 14.91 to 60.95 μM was observed in some compounds. Enzyme kinetic study revealed the most potent compound (6c) as a mixed-type AChE inhibitor. No cytotoxicity from the quinoxaline derivatives was noticed in the human neuroblastoma cell line (SHSY5Y). In silico study suggested the compounds preferred the peripheral anionic site (PAS) to the catalytic anionic site (CAS), which was different from AChE inhibitors (tacrine and galanthamine). We had proposed the molecular design guided for quinoxaline derivatives targeting the PAS site. Therefore, the quinoxaline derivatives could offer the lead for the newly developed candidate as potential acetylcholinesterase inhibitors.

Perturbing pro-survival proteins using quinoxaline derivatives: A structure-activity relationship study

In HeLa cells the combinatorial knockdown of Bcl-xL and Mcl-1 is sufficient to induce spontaneous apoptosis. Quinoxaline derivatives were screened for the induction of Mcl-1 dependent apoptosis using a cell line without functional Bcl-xL. Quinoxaline urea

2,3-Substituted quinoxalin-6-amine analogs as antiproliferatives: A structure-activity relationship study

The quinoxaline core is considered a privileged scaffold as it is found in a variety of biologically relevant molecules. Here we report the synthesis of a quinoxalin-6-amine library, screening against a panel of cancer cell lines and a structure-activity

Novel highly regioselective syntheses of unsymmetrical 2,3-disubstituted quinoxalines

Non-symmetrical 2,3-disubstituted quinoxalines are not easily obtained in good yields because of the lack of regioselectivity of the Hinsberg condensation, or the large number of steps required for achieving their preparation. Two efficient methods leadin

Synthesis and antiprotozoal activity of some new synthetic substituted quinoxalines

A series of 29 new quinoxalines was synthesized and evaluated in vitro against several parasites (Leishmania donovani, Trypanosoma brucei brucei, and Trichomonas vaginalis). Several of them displayed interesting activities, and particularly four quinoxaline amides showed in vitro antileishmanial properties (IC50 less than 20 μM).

Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives

A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R1and R2each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8-positions of the quinoxaline nucleus, and R3, R4and R5each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as reduction in peripheral pain.

Utilisation of 6-amino-2,3-dimethylquinoxaline for the synthesis of tricyclic pyridoquinoxalines via Gould-Jacobs reaction

Treatment of 2,3-dimethylquinoxalin-6-amine with (alkoxymethylidene)malonic derivatives gave the corresponding (quinoxalylamino)ethenes, which on heating cyclized to angularly annelated pyrido[3,2-f]quinoxalin-10-ones.

METHODS FOR USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES

A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: STR1 and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R 1 and R 2 each is independently selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7-or 8-positions of the quinoxaline nucleus, and R 3, R 4 and R 5 each is located in one of the remaining 5-, 6-, 7-or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide treatment for ischemia.

Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure

Certain (2-imidazolin-2-ylamino) quinoxalines are disclosed. Such quinoxalines reduce or maintain intraocular pressure when administered directly to the eye of a mammal.

Thiocyanatoquinoxaline compounds with immunomodulating activity

New thiocyanatoquinoxaline compounds useful as immunomodulating agents which have the general formula: STR1 wherein R is hydrogen, methyl or 5-thiocyanato-2-furanyl; R1 is hydrogen, methyl or 2-furanyl; or R and R1 taken together completes a cyclohexyl ring.